Abstract Number: 1607 • 2013 ACR/ARHP Annual Meeting
Two Year Follow-Up On Biologics Use In 13 Centers- Data From The International Registry For Biologics In Systemic Lupus Erythematosus
Background/Purpose: Only one biologic agent has been approved for use in SLE, but some are used off-label in various settings. To obtain systematic information regarding…Abstract Number: 1608 • 2013 ACR/ARHP Annual Meeting
A Phase I Single-Dose Crossover Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy Of AMG 811 (anti-IFN-gamma) In Subjects With Discoid Lupus Erythematosus
Background/Purpose: Discoid Lupus Erythematosus (DLE) is the most common form of chronic cutaneous LE (CCLE) and develops in up to a quarter of SLE patients.…Abstract Number: 1609 • 2013 ACR/ARHP Annual Meeting
AMG 811 (anti-IFN-gamma) Treatment Leads To a Reduction In The Whole Blood IFN-Signature and Serum CXCL10 In Subjects With Systemic Lupus Erythematosus: Results Of Two Phase I Studies
Background/Purpose: Interferon-gamma (IFN-g) is a major pro-inflammatory cytokine that modulates the function of several important populations of immune cells including B cells, T cells, and…Abstract Number: 1610 • 2013 ACR/ARHP Annual Meeting
Lymphoablation Including B Cell Depletion and Autologous Hematopoietic Stem Cell Transplantation Leads To Long Remissions In Treatment-Resistant Systemic Lupus Erythematosus Patients
Background/Purpose: Over the past two decades, approximately 200 patients with severe systemic lupus erythematosus(SLE) have received autologous hematopoietic stem cell transplants (autoHSCT). More than half…Abstract Number: 1611 • 2013 ACR/ARHP Annual Meeting
Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients
Background/Purpose: Rituximab (Rituxan, Mabthera; RTX) has not been approved for use in SLE, but uncontrolled observations have suggested efficacy in some patients and the medication…Abstract Number: 1612 • 2013 ACR/ARHP Annual Meeting
Rituximab For Treatment Of Refractory Auto-Immune Hepatitis
Background/Purpose: Auto-immune hepatitis (AIH), also known as lupoid hepatitis, is a chronic progressive disease of unknown aetiology. First-line therapy consists of corticosteroids alone or in…Abstract Number: 1613 • 2013 ACR/ARHP Annual Meeting
Anti-Malarial Drugs (hydroxychloroquine and quinacrine) Decrease The Production Of Interferon-Alfa Initiated By TLR-9 Agonist
Background/Purpose: Toll-like receptor 9 (TLR-9) plays an important role in initiating innate immunity. The recognition of self DNA fragments by TLR-9 may results in the…Abstract Number: 1614 • 2013 ACR/ARHP Annual Meeting
Hydroxychloroquine Reverse The Elevation Of Interferon-Alfa Initiated By TLR-9 Agonist Which Irresponsive To Glucocorticoid
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by chronic stimulation of the innate immune system by endogenous nucleic acids through toll-like receptors (TLRs) pathway, which…Abstract Number: 1615 • 2013 ACR/ARHP Annual Meeting
Type I Interferons As a Serum Biomarker Of Subclinical Atherosclerosis In Pediatric Systemic Lupus Erythematosus Patients
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder with a marked increase in cardiovascular (CV) morbidity and mortality due to premature atherosclerosis, distinct…Abstract Number: 1616 • 2013 ACR/ARHP Annual Meeting
Interferon Regulatory Factors 3 and 5 As Key Elements Of The Interferon Signature On Plasmacytoid Dendritic Cells From Systemic Lupus Erythematosus Patients
Background/Purpose: Plasmacytoid dendritic cells (pDC) are considered the main source of type-I interferon (IFN-I). The interferon signature has been widely associated to systemic lupus erythematosus…Abstract Number: 1617 • 2013 ACR/ARHP Annual Meeting
Toll-Like Receptor 3 Plays a Role In Loss Of Tolerance To The Ro/SSA Auto-Antigen In Systemic Lupus Erythematosus
Background/Purpose: Toll-like Receptor (TLR)7 and TLR9 play a role in the pathogenesis of systemic lupus erythematosus (SLE) by inducing Interferon (IFN)-α and IFN-induced genes expression.…Abstract Number: 1618 • 2013 ACR/ARHP Annual Meeting
Chromatin Binding In SLE Patients Correlates With The Intensity Of Apoptotic Binding By 9G4+ B Cells
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-organ autoimmune disease characterised by production of autoantibodies to multiple nuclear antigens, some of which are highly specific…Abstract Number: 1619 • 2013 ACR/ARHP Annual Meeting
In Vitro Assessments Of Mesenchymal Stem Cells From Lupus Patients To Predict Suppressive Function In Vivo
Background/Purpose: Broad immune suppression by mesenchymal stem cells (MSCs) make them an attractive candidate as a cell therapy for autoimmune diseases, such as systemic lupus…Abstract Number: 1620 • 2013 ACR/ARHP Annual Meeting
Characterization Of a Jamaican Lupus Cohort: Proinflammatory Biomarkers and Disease Activity
Background/Purpose: Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are related systemic autoimmune diseases associated with proinflammatory prothrombotic biomarkers/cytokine (PPM) and antiphospholipid antibodies (aPL). Reports…Abstract Number: 1621 • 2013 ACR/ARHP Annual Meeting
T Helper 17 Cells and Interferon Type I: Partners In Crime In SLE?
Background/Purpose: A hallmark of systemic autoimmune diseases, such as systemic lupus erythematotsus (SLE), is the increased expression of interferon (IFN) type I inducible genes, the…